Phenothiazinyl-thiazolotriazole hybrids as potential EGFR-inhibitory anticancer agents: synthesis, biological evaluation and computational studies.
Abstract
A series of novel phenothiazinyl-thiazolotriazole hybrids (8a-8l) were synthesized via molecular hybridization of the phenothiazine and thiazolotriazole pharmacophores and characterized by spectroscopic techniques. In vitro cytotoxicity against MCF-7 and MDA-MB-231 breast cancer cell lines (MTT assay) revealed that electron-withdrawing substituents markedly enhanced activity, with 8k, 8i and 8e emerging as the most potent analogues (IC50 = 3.68 to 6.37 μM against MCF-7; 4.01 to 7.11 μM against MDA-MB-231), comparable to or exceeding erlotinib; compounds 8f, 8h, and 8j also showed appreciable activity with favorable selectivity toward the non-tumorigenic MCF-10A cell line. EGFR tyrosine kinase inhibition studies showed that 8k (IC50 = 0.352 μM) surpassed erlotinib (IC50 = 0.436 μM), while 8i and 8e were comparably potent. Molecular docking against EGFR (PDB: 4HJO) revealed strong predicted docking scores across the series (-8.65 to -11.50 kcal/mol), with 8k showing the most favorable predicted docking energy, stabilized by key hydrogen bonding interactions, while 8j engaged an additional halogen-bonding contact. Normal mode analysis (iMODS) of the docked EGFR complexes offered a complementary, physics-based assessment of relative conformational flexibility and mechanical rigidity beyond a visual inspection of the docked poses, with 8k and 8i showing the greatest mechanical rigidity among the profiled compounds, consistent with their more favorable predicted docking energies and enzymatic potency. The DFT calculations showed that 8e, 8i and 8k had the smallest HOMO-LUMO gaps and the highest electrophilicity among the series, a trend that correlates with, though does not by itself establish, their superior biological activity. An in silico ADMET study comprising BOILED-Egg profiling of the six highest compounds (8e, 8f, 8i, 8j and 8k) identified 8e as the best balanced in terms of drug-likeness, absorption and toxicity profile, while 8k showed lower drug-likeness and a mutagenicity signal. Integrated results of these studies indicate 8e, 8i and 8k as promising EGFR-inhibitory anticancer leads for future preclinical investigation; selectivity toward EGFR relative to other kinases was not assessed in this study and remains to be established.